肺癌免疫治疗进展  

Development in immunotherapy of lung cancer

作　　者：刘杰[1] 赵田 李钦传[1] 陈国涵[1] LIU Jie;ZHAO Tian;LI Qinchuan;CHEN Guohan(Department of Thoracic Surgery,Shanghai East Hospital,Tongji University School of Medicine,Shanghai,200120,P.R.China)

机构地区：[1]同济大学附属东方医院胸外科,上海200120

出　　处：《中国胸心血管外科临床杂志》2022年第11期1517-1524,共8页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

基　　金：国家自然科学基金(8180111604)。

摘　　要：肺癌是导致全球癌症患者死亡的最主要原因。尽管基于铂类的化学疗法和基于酪氨酸激酶抑制剂的分子靶向疗法取得了进展性的治疗效果,但它们也存在自身的局限性。免疫治疗最近已经成为一种非常有效的新型疗法,全球医务工作者对癌症免疫疗法的热情日益高涨。本文总结了免疫检查点抑制剂在临床试验中的效果,抗程序性死亡受体-1(programmed death-1,PD-1)/程序性死亡配体-1(programmed death-ligand 1,PD-L1)药物在肺癌治疗中的现状和进展,概述了影响抗PD-1/PD-L1治疗效果的不良事件以及减少这些事件发生的可能因素。Lung cancer is the leading cause of cancer-related deaths worldwide.Although improvement has been achieved in platinum-based chemotherapy and tyrosine kinase inhibitors-based molecular targeted therapy,they still have limitations.Immunotherapy has recently emerged as a very effective new treatment,and there is now growing enthusiasm in cancer immunotherapy worldwide.We summarized the effects of immune checkpoint inhibitors in clinical trials,and the current status and progress of anti programmed death-1(PD-1)/programmed death-ligand 1(PD-L1)agents in lung cancer treatment.Attention has been paid to finding out the factors which influence the therapeutic effect of anti-PD-1/PD-L1 therapy and reducing the occurrence of adverse events.

关 键 词：肺癌 免疫治疗 免疫检查点抑制剂 程序性死亡受体-1 程序性死亡配体-1 不良事件 综述 

分 类 号：R734.2[医药卫生—肿瘤]